DUBLIN--(BUSINESS WIRE)--Dublin - Research and Markets (http://www.researchandmarkets.com/research/j6qx84/postmenopausal_vag) has announced the addition of GlobalData 's new report "Postmenopausal Vaginal Atrophy Therapeutics - Pipeline Assessment and Market Forecasts to 2019" to their offering.
GlobalData, the industry analysis specialist, has released its new report, Postmenopausal Vaginal Atrophy Therapeutics - Pipeline Assessment and Market Forecasts to 2019. The report is an essential source of information on the global postmenopausal vaginal atrophy therapeutics market, and provides analysis of a number of key areas.
The report identifies the key trends shaping and driving the global postmenopausal vaginal atrophy therapeutics market and provides insights into the current competitive landscape and emerging companies expected to significantly alter the market positioning of current market leaders. Most importantly, the report provides valuable insights into the pipeline products within the global postmenopausal vaginal atrophy sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
Postmenopausal Vaginal Atrophy Therapeutics Market is Forecast to Witness High Growth until 2019
GlobalData's analysis indicates that the global postmenopausal vaginal atrophy therapeutics market was worth $1,634.5m in 2011, after increasing at a Compound Annual Growth Rate (CAGR) of 8.0% during 2006-2011.The market is expected to grow at a CAGR of 8.5% during 2011-2019 to $3,144.3m in 2019. Estrogen Replacement Therapy (ERT) is the mainstay of treatment for postmenopausal vaginal atrophy patients.
The currently used treatment options can be divided into four categories: vaginal cream, vaginal tablets, vaginal rings and oral estradiol, all of which are types of ERT. Estrace cream (estradiol) by Warner Chilcott and Premarin cream (conjugated estradiol) by Pfizer are examples of vaginal creams, while Vagifem (estradiol) is a vaginal tablet and is marketed by Novo Nordisk. Femring (estradiol, extended release) by Warner Chilcott and Estring (estradiol acetate, extended release) by Pfizer are types of vaginal ring.
Companies Mentioned
- Bionovo, Inc. (Bionovo)
- QuatRx Pharmaceutical Company
- Shionogi & Co.
- EndoCeutics, Inc
- Bayer AG
For more information visit http://www.researchandmarkets.com/research/j6qx84/postmenopausal_vag
Source: GlobalData